Reaction

Injection Site Vesicles reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,926 reports · 70 co-occurring drugs

As of the last recalculation, Injection Site Vesicles appears in 5,926 FAERS reports alongside 70 co-occurring drug terms. The strongest observed disproportionality signal is FREMANEZUMAB-VFRM (PRR 11.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Fremanezumab-Vfrm	37	11.4	11.4
Inclisiran	18	7.9	7.9
Dupilumab	892	7.5	7.5
Asfotase Alfa	21	7.4	7.4
Glatiramer Acetate	120	7.2	7.2
Tirzepatide	282	6.4	6.4
Galcanezumab-Gnlm	55	6.2	6.2
Adalimumab	1,053	6.1	6.1
Anakinra	27	5.7	5.7
Oral Semaglutide	115	5.6	5.6
Etanercept	818	5.4	5.4
Evolocumab	221	4.9	4.9
Abaloparatide	40	4.8	4.8
Peginterferon Beta-1A	17	4.6	4.6
Sarilumab	34	4.5	4.5
Ixekizumab	40	3.8	3.8
Clobetasol Propionate Ointment Usp, 0.05%	11	3.8	3.8
Clobetasol Propionate	11	3.7	3.7
Dulaglutide	90	3.6	3.6
Alirocumab	25	3.5	3.5
Pegvaliase-Pqpz	8	3.4	3.4
Certolizumab Pegol	110	3.3	3.3
Azelastine	16	3.1	3.1
Octreotide Acetate	27	3.1	3.1
Cetirizine Hcl	8	3.1	3.1
Hyoscyamine Sulfate	8	3.1	3.1
Cabotegravir	7	3.0	3.0
Romosozumab-Aqqg	11	2.8	2.9
Triamcinolone Acetonide Ointment Usp, 0.05%	18	2.7	2.7
Bimekizumab	16	2.6	2.6
Ketoconazole Foam	11	2.6	2.6
Meloxicam	43	2.6	2.6
Ketoconazole Cream, 2%	11	2.6	2.6
Fondaparinux Sodium	6	2.6	2.6
Canakinumab	8	2.6	2.6
Risankizumab-Rzaa	60	2.6	2.6
Interferon Beta-1B	14	2.6	2.6
Liraglutide	34	2.4	2.4
Somatropin	49	2.4	2.4
Erenumab-Aooe	36	2.3	2.3
Guanfacine	5	2.2	2.2
Mesalamine	35	2.2	2.2
Naltrexone	19	2.2	2.2
Triamcinolone Acetonide	19	2.2	2.2
Teriparatide	68	2.1	2.1
Exenatide	30	2.0	2.0
Multivitamin	28	2.0	2.0
Onabotulinumtoxina	43	2.0	2.0
Levocetirizine Dihydrochloride	13	1.9	1.9
Teduglutide	7	1.8	1.8
Belimumab	16	1.8	1.8
Treprostinil	61	1.7	1.7
Interferon Beta-1A	93	1.7	1.7
Botulinum Toxin Type A	6	1.7	1.7
Alteplase	7	1.6	1.6
Fexofenadine Hydrochloride	10	1.6	1.6
Buprenorphine	42	1.6	1.6
Ofatumumab	14	1.5	1.5
Dronedarone	4	1.4	1.4
Secukinumab	57	1.2	1.2
Peginterferon Alfa-2A	19	1.2	1.2
Guselkumab	12	1.2	1.2
Nemolizumab-Ilto	4	1.1	1.1
Crisaborole	3	1.1	1.1
Leuprolide Acetate	23	1.0	1.0
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	12	1.0	1.0
Budesonide, Glycopyrrolate, And Formoterol Fumarate	3	1.0	1.0
Rimegepant Sulfate	3	0.8	0.8
Paliperidone Palmitate	6	0.7	0.7
Etonogestrel	8	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.